The Acute Management of Newly Diagnosed Atrial Fibrillation in Critically Ill Patients. The Role of Landiolol in Clinical Practice.
Physicians to manage an arrhythmia in critically ill patients should take into consideration many parameters. The choice of a suitable medicinal agent is a very challenging decision-making process. Critically ill patients frequently present with comorbidities as heart failure. In challenging cases, the assistance of cardiologists is often requested.
Rapibloc is a medicinal agent for life-critical conditions, where it is desirable to safely and rapidly reduce heart rate with limited effect in blood pressure and inotropy (e.g. pts in sepsis, pts with heart failure).
After this webinar has finished, we would love to hear your thoughts. Please click the link here: https://forms.office.com/r/aAK8DhK8pJ
This broadcast is supported by:
Welcome and Introduction
A novel super-selective intravenous beta-blocker in management Atrial Fibrillation (AF) during ICU stay
Rate vs Rhythm control for management POAF in critical ill patients. Examples from life experience
- ICU patient profile
- Limitations of current therapeutic options for the management of AF in ICU patients
- Landiolol properties (Pharmacokinetic – Pharmacodynamic profile)
- AF Triggers During Critical Illness
- Rate vs Rhythm control
- Landiolol is sepsis pts
- Safe co-administration of landiolol in patients on catecholamine support
- Cardiologists who advice Intensivists for the management of arrhythmias in ICU
- Cardiologists who work in ICUs
- Cardiologists who work in Coronary Care Units
Anna Vachulova is a cardiologist at Slovak National Institute of Cardiovascular Diseases, Bratislava (Slovakia).
She completed her medical degree and PhD studies at the Comenius University in Bratislava, Slovakia. She continued her training in Bratislava; in the Dept of Anesthesiology at Slovak National Institute of Cardiovascular Diseases, in the Dept of Internal Medicine University Hospital, at the Comenius University, in the Dept of Cardiology (Arrhythmia and Pacemaker implantation) and currently in the Department of Heart Failure and Heart Transplantation at the Slovak National Institute of Cardiovascular Diseases.
She completed her specialist training in Internal Medicine and later in Cardiology at Slovak Medical University, Bratislava.
Between 2013 and 2015 she attended specialist training in heart failure and graduated with the Certificate of Advanced Studies at University of Zurich in Heart Failure - in collaboration with the ESC, the HFA.
She has a special interest in arrhythmias especially AF, anticoagulation treatment, LAAO, heart failure, intensive care medicine and arterial hypertension.
Dr Psallida is a pulmonologist, intensivist and attending physician in ICU. She works at General and Oncologic Hospital of Kifisia "AGIOI ANARGIROI" Athens - Greece.
Dr Gheorghe-Andrei Dan is Head of Internal Medicine University Clinic, Colentina University Hospital, Bucharest and Head of the Cardiology Department and Diagnostic Cardiovascular Procedures and Arrhythmology Unit – University Hospital Colentina.
Professor – Internal Medicine Department of the University of Medicine and Pharmacy “Carol Davila” Bucharest
Head, Internal Medicine Chair, University of Medicine and Pharmacy “Carol Davila” Bucharest
Leading Research Investigator of the Romanian Academy of Medical Sciences
Chancellor (Scientific Secretary), Faculty of Medicine, University of Medicine “Carol Davila”- Bucharest
Dr Gheorghe-Andrei Dan is on the Editorial Board of European Cardiology Review.